Lucid Diagnostics’ (LUCD) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD) in a research report report published on Thursday morning,Benzinga reports. Needham & Company LLC currently has a $3.00 target price on the stock.

Several other brokerages have also recently commented on LUCD. Weiss Ratings reissued a “sell (d-)” rating on shares of Lucid Diagnostics in a research report on Wednesday, November 5th. Wall Street Zen upgraded shares of Lucid Diagnostics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 14th. BTIG Research raised their price target on Lucid Diagnostics from $2.00 to $2.50 and gave the stock a “buy” rating in a research report on Friday, September 5th. Finally, Ascendiant Capital Markets boosted their price objective on shares of Lucid Diagnostics from $7.75 to $8.00 and gave the company a “buy” rating in a research report on Monday, October 6th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $3.88.

Lucid Diagnostics Price Performance

Shares of LUCD stock opened at $1.07 on Thursday. Lucid Diagnostics has a 12-month low of $0.75 and a 12-month high of $1.80. The firm has a fifty day moving average of $1.13 and a 200-day moving average of $1.17. The company has a market capitalization of $147.32 million, a price-to-earnings ratio of -1.03 and a beta of 1.22.

Lucid Diagnostics (NASDAQ:LUCD) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04). The firm had revenue of $1.21 million during the quarter, compared to the consensus estimate of $1.35 million. On average, equities analysts expect that Lucid Diagnostics will post -0.84 EPS for the current year.

Insider Buying and Selling at Lucid Diagnostics

In other news, Director Dennis Matheis bought 100,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The stock was acquired at an average price of $1.02 per share, with a total value of $102,000.00. Following the completion of the purchase, the director directly owned 665,443 shares of the company’s stock, valued at approximately $678,751.86. This represents a 17.69% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 6.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Alyeska Investment Group L.P. acquired a new position in Lucid Diagnostics in the first quarter valued at approximately $2,813,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Lucid Diagnostics in the 1st quarter valued at $37,000. Goldman Sachs Group Inc. lifted its position in shares of Lucid Diagnostics by 35.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company’s stock valued at $129,000 after acquiring an additional 22,727 shares during the period. Ghisallo Capital Management LLC bought a new position in Lucid Diagnostics during the first quarter worth $629,000. Finally, Parallel Advisors LLC bought a new position in Lucid Diagnostics during the second quarter worth $46,000. 74.01% of the stock is owned by institutional investors.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.